Hangeshashinto Improves the Completion Rate of Chemoradiotherapy and the Nutritional Status in Patients with Head and Neck Cancer

Hatakeyama, Hiromitsu; Takahashi, Hiroki; Oridate, Nobuhiko; Kuramoto, Rinnosuke; Fujiwara, Keishi; Homma, Akihiro; Takeda, Hiroshi; Fukuda, Satoshi

Hangeshashinto Improves the Completion Rate of Chemoradiotherapy and the Nutritional Status in Patients with Head and Neck Cancer

Hatakeyama, Hiromitsu; Takahashi, Hiroki; Oridate, Nobuhiko et al.

ORL-journal for oto-rhino-laryngology head and neck surgery, 2015, 77(2), 100-108

Permalink : https://hdl.handle.net/2115/59425

このアイテムのアクセス数:1,620件（2026-08-09 17:38 集計）

閲覧可能ファイル

ファイル	フォーマット	サイズ	閲覧回数	説明
manuscript	pdf	993 KB	1,613

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

アクセス権	open access
URI	https://hdl.handle.net/2115/59425
タイトル	Hangeshashinto Improves the Completion Rate of Chemoradiotherapy and the Nutritional Status in Patients with Head and Neck Cancer
著者	Hatakeyama, Hiromitsu ; Takahashi, Hiroki ; Oridate, Nobuhiko ; Kuramoto, Rinnosuke ; Fujiwara, Keishi ; Homma, Akihiro ; Takeda, Hiroshi ; Fukuda, Satoshi
e-Rad_Researcher 10455652 著者名 Hatakeyama, Hiromitsu
著者名 Takahashi, Hiroki
e-Rad_Researcher 90312355 著者名 Oridate, Nobuhiko
著者名 Kuramoto, Rinnosuke
著者名 Fujiwara, Keishi
e-Rad_Researcher 30312359 著者名 Homma, Akihiro
e-Rad_Researcher 60261294 著者名 Takeda, Hiroshi
e-Rad_Researcher 20125347 著者名 Fukuda, Satoshi
言語	英語
キーワード	Mucositis
	Hangeshashinto
	Chemoradiotherapy
	Head and neck cancer
	Nutrition
発行日	2015-05
出版者	Karger
収録物名	ORL-journal for oto-rhino-laryngology head and neck surgery
巻(号)	77(2)
ページ	100-108
抄録	Purpose: Severe oral and pharyngeal mucositis is one of the most critical toxicities known to lead to the discontinuation of chemoradiotherapy (CRT) for head and neck cancer (HNC). Hangeshashinto (TJ-14) is a Kampo medicine that relieves chemotherapy-induced oral mucositis. We. investigated the effect of TJ-14 on mucositis, nutritional status, and the completion rate of CRT. Methods: The study group comprised patients with advanced HNC who were treated with concomitant weekly cisplatin and 70 Gy of radiotherapy. The primary endpoint was the completion rate of chemotherapy, and the secondary endpoints were the grade of mucositis and the nutritional status. Results: A total of 57 patients were included in this study. The completion rate of CRT among patients who were treated with TJ-14 was 91.4%. There was a significant difference in the completion rate of CRT between the groups treated with and without TJ-14 (p = 0.0452). The reduction in body weight was significantly improved from 10.89 to 5.89% with TJ-14 administration (p = 0.003), and the reduction in serum albumin was also significantly decreased from 17.37 to 8.73%. (p = 0.024). Conclusion: This therapy allowed a high completion rate of CRT as well as significant benefits in terms of nutritional status. We plan to carry out a further large-scale study of TJ-14. (C) 2015 S, Karger AG, Basel
資源タイプ	学術雑誌論文
出版タイプ	Accepted Manuscript
PISSN	0301-1569
関連情報	PMID 25896416
関連情報 (isVersionOf)	出版社版DOI https://doi.org/10.1159/000381026